LENZ Therapeutics, Inc. (NASDAQ:LENZ) is one of the stocks Jim Cramer recently gave takes on. Commenting on the company’s eyedrops, VIZZ, Cramer said: “Overall, I’m inclined to believe that there’ll be enough patients eager to try the product. We’re talking a total addressable market of 128 million people. You don’t need to get that many in order to have a big hit here. Of course, if you buy LENZ here, you’re not early to the story. Stock’s… up nearly 150% from its April lows… If you buy LENZ here, you’re ...

产品信息 - 公司旗下产品VIZZ获得FDA批准 较原计划提前一周 [1] - VIZZ是一种治疗老花眼的滴眼液产品 [1] - 老花眼是一种随着年龄增长出现的近视力丧失症状 通常从45岁开始影响人群 [2] 市场机会 - 老花眼影响所有年龄增长人群 具有广泛的患者基础 [2] - 该疾病表现为需要将手机等物体拿得更远才能看清 [2] 公司动态 - 公司目前处于业务活跃期 有多项进展同时进行 [1] - 公司管理层包括总裁、首席执行官、秘书兼董事Evert Schimmelpennink [1]